New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT05841563
Summary
This is an early-stage study testing a new intravenous cancer drug called PM54 in patients with advanced solid tumors that have progressed after standard treatments. The main goals are to find the safest dose, understand how the body processes the drug, and look for early signs that it might help control tumor growth. The study will enroll about 125 adults with specific types of advanced cancers, including certain lung, skin, gynecological, and other solid tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HM Universitario Sanchinarro
RECRUITINGMadrid, M, 28050, Spain
Contact
-
Institut Jules Bordet
RECRUITINGAnderlecht, 1070, Belgium
Contact
-
South Texas Accelerated Research Therapeutics
RECRUITINGSan Antonio, Texas, 78229-3307, United States
Contact
Conditions
Explore the condition pages connected to this study.